...
首页> 外文期刊>BMC Nephrology >The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study
【24h】

The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study

机译:添加的白蛋白可增强速尿对低白蛋白血症慢性肾脏病患者的利尿作用:一项随机对照研究

获取原文
           

摘要

Background Chronic kidney disease (CKD) with edema is a common clinical problem resulting from defects in water and solute excretion. Furosemide is the drug of choice for treatment. In theory, good perfusion and albumin are required for the furosemide to be secreted at the tubular lumen. Thus, in the situation of low glomerular filtration rate (GFR) and hypoalbuminemia, the efficacy of furosemide alone might be limited. There has been no study to validate the effectiveness of the combination of furosemide and albumin in this condition. Methods We conducted a randomized controlled crossover study to compare the efficacy of diuretics between furosemide alone and the combination of furosemide plus albumin in stable hypoalbuminemic CKD patients by measuring urine output and sodium. The baseline urine output/sodium at 6 and 24 hours were recorded. The increment of urine output/sodium after treatment at 6 and 24 hours were calculated by using post-treatment minus baseline urine output/sodium at the corresponding period. Results Twenty-four CKD patients (GFR = 31.0?±?13.8 mL/min) with hypoalbuminemia (2.98?±?0.30 g/dL) were enrolled. At 6 hours, there were significant differences in the increment of urine volume (0.47?±?0.40 vs 0.67?±?0.31 L, P?vs 55.0?±?26.7 mEq, P?vs 0.59?±?0.50 L, P = 0.46) and urine sodium (65.3?±?47.5 vs 76.1?±?50.1 mEq, P = 0.32) between the two groups. Conclusion The combination of furosemide and albumin has a superior short-term efficacy over furosemide alone in enhancing water and sodium diuresis in hypoalbuminemic CKD patients. Trial registration The Australian New Zealand Clinical Trials Registration (ANZCTR12611000480987)
机译:背景技术患有水肿的慢性肾脏疾病(CKD)是由水和溶质排泄缺陷引起的常见临床问题。速尿是治疗的首选药物。理论上,速尿要分泌到管状内腔需要良好的灌注和白蛋白。因此,在低肾小球滤过率(GFR)和低白蛋白血症的情况下,单独使用速尿的疗效可能会受到限制。尚无研究证实呋塞米和白蛋白联合治疗在这种情况下的有效性。方法我们进行了一项随机对照交叉研究,通过测量尿量和血钠,比较速尿单独使用速尿和速尿联合白蛋白联合治疗稳定的低白蛋白血症CKD患者的利尿剂疗效。记录6和24小时的基线尿量/钠。通过使用治疗后减去相应时间段的基线尿量/钠来计算6和24小时治疗后尿量/钠的增量。结果招募了24例低蛋白血症(2.98±±0.30 g / dL)的CKD患者(GFR = 31.0±±13.8 mL / min)。在6小时时,尿量的增加存在显着差异(0.47±±0.40 vs 0.67±±0.31 L,P≥vs55.0±±26.7 mEq,P≥vs0.59±±0.50 L,P =两组之间的尿钠(0.46)和尿钠(65.3±±47.5 vs 76.1±±50.1 mEq,P = 0.32)。结论速尿和白蛋白联用对低白蛋白血症性CKD患者的水和钠利尿作用优于单用速尿。试验注册澳大利亚新西兰临床试验注册(ANZCTR12611000480987)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号